KIMBERLY-CLARK PROFESSIONAL* announces the latest in contamination control for sterile environments: the KIMTECH PURE* M3 Sterile Pouch Facemask, designed for maximum bacterial and particle filtration.
New sterile pouch-style cleanroom mask provides superior breathability, comfort and airflow
KIMBERLY-CLARK PROFESSIONAL* announces the latest in contamination control for sterile environments: the KIMTECH PURE* M3 Sterile Pouch Facemask. The facemask is recommended for use in ISO Class 5 or higher cleanrooms.
The mask’s pouch design and large breathing chamber reduce the chance for particle build-up. Its consistently tight seal helps to reduce goggle fogging and the risk of escaping particles.
“A protective, comfortable facemask means better performance,” explains Jamie Cassar, Category manager, KIMBERLY-CLARK PROFESSIONAL* EMEA. “And better performance means better protection, which is important in sterile environments that require constant monitoring to prevent contamination.”
The mask’s two knitted headbands are comfortable and help to hold the mask in place while it’s being worn. Additional comfort is provided by the mask’s fabric inner facing.
Made of apertured, low-lint polyethylene film for protection against contamination, the KIMTECH PURE* M3 Sterile Pouch Facemask contains no natural rubber latex, thus reducing the risk of allergic reactions. The masks are individually packaged and triple-bagged for extra protection. They are gamma irradiated with a Sterility Assurance Level (SAL) of 10-6. Certificates of Irradiation are available online at www.kimtech.com/certificates.
For further information, please send an e-mail to Kimtech.support@kcc.com or visit www.contaminomics.com.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.